Sutro Biopharma, Inc. (STRO)

Sutro Biopharma Stock Forecast

Stock Price Forecast

The 6 analysts that cover Sutro Biopharma stock have a consensus rating of "Hold" and an average price target of $19.67, which forecasts a 118.56% increase in the stock price over the next year. The lowest target is $8.00 and the highest is $30.

Price Target: $19.67 (+118.56%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	$8.00	$19.67	$20	$30
Change	-11.11%	+118.56%	+122.22%	+233.33%

* Price targets were last updated on Aug 12, 2025.

Analyst Ratings

The average analyst rating for Sutro Biopharma stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Jul '25	Aug '25	Sep '25	Oct '25	Nov '25	Dec '25
Strong Buy	1	1	1	1	1	0
Buy	1	1	1	1	1	1
Hold	4	5	5	5	5	5
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	7	8	8	8	8	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Derek Archila Wells Fargo	Wells Fargo	Hold Maintains $40 → $30	Hold	Maintains	$40 → $30	+233.33%	Aug 12, 2025
Edward Tenthoff Piper Sandler	Piper Sandler	Hold → Buy Upgrades $20	Hold → Buy	Upgrades	$20	+122.22%	Jun 16, 2025
Tazeen Ahmad B of A Securities	B of A Securities	Sell Maintains $10 → $8	Sell	Maintains	$10 → $8	-11.11%	May 19, 2025
Andres Maldonado HC Wainwright & Co.	HC Wainwright & Co.	Hold Reiterates $20	Hold	Reiterates	$20	+122.22%	Apr 29, 2025
Andrew Fein HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy → Hold Downgrades $120 → $20	Strong Buy → Hold	Downgrades	$120 → $20	+122.22%	Mar 17, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

100.89M

Increased by 62.61%

from 62.04M

Revenue Next Year

46.45M

Decreased by -53.96%

from 100.89M

EPS This Year

-2.15

from -29.61

EPS Next Year

-1.32

from -2.15

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	42.72M	61.88M	67.77M	153.73M	62.04M	100.89M	46.45M
Revenue Growth	-0.03%	44.84%	9.52%	126.84%	-59.64%	62.61%	-53.96%
EPS	-9.90	-22.88	-23.49	-17.75	-29.61	-2.15	-1.32
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	12	12

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	115.5M	98.6M
Avg	100.9M	46.5M
Low	89.0M	n/a

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	86.2%	-2.3%
Avg	62.6%	-54.0%
Low	43.5%	-

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	-1.97	-0.63
Avg	-2.15	-1.32
Low	-2.16	-1.91

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.